Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 9/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211735 | 0.85 | CYP2A6 (0.47) | CYP2A6DYRK1AALDH1A1TSHRKDM4E | |
| SCHEMBL16977154 | 0.79 | PTGES (0.56) | DYRK1AALDH1A1TSHRKDM4EPTGES | |
| SCHEMBL5144216 | 0.78 | CYP2A6 (0.65) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3929218 | 0.77 | CYP2A6 (0.52) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL18224030 | 0.77 | CYP2A6 (0.47) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5204810 | 0.76 | MAOB (0.56) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6683885 | 0.75 | CYP2A6 (0.46) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6273210 | 0.75 | LMNA (0.63) | CYP2A6DYRK1ACHRM2CHRM4CHRM5 | |
| SCHEMBL1068378 | 0.75 | MAOB (0.49) | ALDH1A1KDM4EHSD17B10MAPTALOX15 | |
| SCHEMBL145841 | 0.74 | CYP2A6 (0.45) | CYP2A6CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2020-06-18 | — | — | US | disclosed |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190092778-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2019-03-28 | — | — | US | disclosed |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
| WO-2018064135-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| US-8541579-B2 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | GLAXO GROUP LIMITED | 2009-07-23 | — | — | US | disclosed |
| US-7514437-B2 | Substituted diketopiperazines as oxytocin antagonists | SMITHKLINE BEECHAM CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1943222-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1458393-B1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| CN-100374115-C | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LTD (GB) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| CN-1606443-A | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LTD (GB) | 2005-04-13 | — | — | CN | disclosed |
| WO-2005000311-A1 | SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | disclosed |
| US-5438074-A | 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents | PFIZER INC. (US) | 1995-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | CYP2A6 1697/4885DYRK1A 3251/4885CHRM2 66/4885 |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | CYP2A6 1697/4885DYRK1A 3251/4885CHRM2 66/4885 |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | OXTR, AVPR2, AVPR1B | CYP2A6 2600/4885DYRK1A 2442/4885CHRM2 2065/4885 |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | CYP2A6 1697/4885DYRK1A 3251/4885CHRM2 66/4885 |
| US-20190092778-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | CYP2A6 1697/4885DYRK1A 3251/4885CHRM2 66/4885 |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | CYP2A6 1697/4885DYRK1A 3251/4885CHRM2 66/4885 |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | CYP2A6 1697/4885DYRK1A 3251/4885CHRM2 66/4885 |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | OXTR, AVPR2, CRH | CYP2A6 3509/4885DYRK1A 1738/4885CHRM2 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.